Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review

Bibliography

• Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363:1981-5
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ; Centers for Disease C, Prevention. Drug-induced deaths - United States, 2003-2007. MMWR Surveill Summ 2011;60(Suppl):60-1
   PubMedGoogle Scholar
• Substance Abuse and Mental Health Services Administration. Office of Applied Studies. The DAWN Report: trends in emergency department visits involving nonmedical use of narcotic pain relievers. Rockville, MD; June 18 2010. Available from: http://store.samhsa.gov/product/Trends-in-Emergency-Department-Visits-Involving-Nonmedical-Use-of-Narcotic-Pain-Relievers/DAWN10-0618 [Last accessed 14 June 2014]
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Substance Abuse and Health Services Administration, Rockville, MD; 2013. Available from: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm [Last accessed 14 June 2014]
   Google Scholar
• Warner M, Chen LH, Makuc DM, et al. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief. 2011;81:1-8
   Google Scholar
• Kochanek KD, Xu J, Murphy SL, et al. Deaths: preliminary data for 2009. Natl Vit Stat Rep 2011;59:51
   Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies - tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-6
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010. MMWR. Morb Mortal Wkly Rep 2012;61:493-7
   PubMedGoogle Scholar
• Foldes FF. The human pharmacology and clinical use of narcotic antagonists. Med Clin North Am 1964;48:421-43
   PubMed Web of Science ®Google Scholar
• Foldes FF, Duncalf D, Kuwabara S. The respiratory, circulatory, and narcotic antagonistic effects of nalorphine, levallorphan, and naloxone in anaesthetized subjects. Can Anaesth Soc J 1969;16:151-61
   PubMedGoogle Scholar
• Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010;112:226-38
   PubMed Web of Science ®Google Scholar
• Lewenstein MJ, Fishman J. Morphine derivative. US3254088; 1966. Available from: http://www.freepatentsonline.com/3254088.html [Last accessed 21 June 2014]
   Google Scholar
• Martin WR. Naloxone. Ann Intern Med 1976;85:765-8
   PubMed Web of Science ®Google Scholar
• Foldes FF, Lunn JN, Moore J, Brown IM. N-Allylnoroxy-morphone: a new potent narcotic antagonist. Am J Med Sci 1963;245:23-30
   PubMed Web of Science ®Google Scholar
• Sgherza AL, Axen K, Fain R, et al. Effect of naloxone on perceived exertion and exercise capacity during maximal cycle ergometry. J Appl Physiol 2002;93:2023-8
   PubMed Web of Science ®Google Scholar
• Mannelli M, Maggi M, De Feo ML, et al. Effects of naloxone on catecholamine plasma levels in adult men. A dose-response study. Acta Endocrinol (Copenh) 1984;106:357-61
   PubMedGoogle Scholar
• Jasinski DR, Martin WR, Haertzen CA. The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). J Pharmacol Exp Ther 1967;157:420-6
   PubMed Web of Science ®Google Scholar
• Foldes FF, Schapira M, Torda TA, et al. Studies on the specificity of narcotic antagonists. Anesthesiology 1965;26:320-8
   PubMed Web of Science ®Google Scholar
• Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet 1976;1(3):219-30
   PubMedGoogle Scholar
• Dowling J, Isbister GK, Kirkpatrick CM, et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008;30:490-6
   PubMed Web of Science ®Google Scholar
• Middleton LS, Nuzzo PA, Lofwall MR, et al. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 2011;106:1460-73
   PubMed Web of Science ®Google Scholar
• Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000;61:85-94
   PubMed Web of Science ®Google Scholar
• Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988;44:335-42
   PubMed Web of Science ®Google Scholar
• Nelson LS, Howland MA. Opioid Antagonists. In: Hoffman RS, Howland MA, Lewin NA, et al. Goldfrank’s Toxicologic Emergencies, 10th edition. McGraw-Hill; New York: 2015
   Google Scholar
• Berkowitz BA, Ngai SH, Hempstead J, Spector S. Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther 1975;195:499-504
   PubMed Web of Science ®Google Scholar
• Kaufman JJ, Semo NM, Koski WS. Microelectrometric titration measurement of the pKa’s and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependence. J Med Chem 1975;18:647-55
   PubMed Web of Science ®Google Scholar
• Kim S, Wagner HNJr, Villemagne VL, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med 1997;38:1726-31
   PubMed Web of Science ®Google Scholar
• Melichar JK, Nutt DJ, Malizia AL. Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol 2003;459:217-19
   PubMed Web of Science ®Google Scholar
• Yassen A, Olofsen E, van Dorp E, et al. Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers. Clin Pharmacokinet 2007;46(11):965-80
   PubMed Web of Science ®Google Scholar
• van Dorp E, Yassen A, Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf 2007;6:125-32
   PubMed Web of Science ®Google Scholar
• Hospira, Inc. Package insert: Naloxone hydrochloride. Available from: http://www.hospira.com/Images/EN-1367_32-5515_1.pdf [Last accessed 1 May 2014]
   Google Scholar
• Carroll FI, Lewin AH, Mascarella SW, et al. Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci 2012;1248:18-38
   PubMed Web of Science ®Google Scholar
• Kane BE, Svensson B, Ferguson DM. Molecular recognition of opioid receptor ligands. AAPS J 2006;8:E126-37
   PubMed Web of Science ®Google Scholar
• Portoghese PS, Sultana M, Takemori AE. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. J Med Chem 1990;33:1714-20
   PubMed Web of Science ®Google Scholar
• Olofsen E, van Dorp E, Teppema L, et al. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology 2010;112:1417-27
   PubMed Web of Science ®Google Scholar
• Yassen A, Olofsen E, Romberg R, et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007;81:50-8
   PubMed Web of Science ®Google Scholar
• Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend 2007;90:261-9
   PubMed Web of Science ®Google Scholar
• Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003;70:S13-27
   PubMed Web of Science ®Google Scholar
• van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006;105:51-7
   PubMed Web of Science ®Google Scholar
• Sarton E, Teppema L, Dahan A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Med Biol 2008;605:486-91
   PubMed Web of Science ®Google Scholar
• Yassen A, Olofsen E, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp ther 2005;313:1136-49
   PubMed Web of Science ®Google Scholar
• van Dorp E, Sarton E, Romberg R, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006;105:51-7
   PubMed Web of Science ®Google Scholar
• Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 1985;57:192-6
   PubMed Web of Science ®Google Scholar
• Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011;59:385-90
   PubMed Web of Science ®Google Scholar
• Maio RF, Gaukel B, Freeman B. Intralingual naloxone injection for narcotic-induced respiratory depression. Ann Emerg Med 1987;16:572-3
   PubMed Web of Science ®Google Scholar
• Tandberg D, Abercrombie D. Treatment of heroin overdose with endotracheal naloxone. Ann Emerg Med 1982;11:443-5
   PubMed Web of Science ®Google Scholar
• Mycyk MB, Szyszko AL, Aks SE. Nebulized naloxone gently and effectively reverses methadone intoxication. J Emerg Med 2003;24:185-7
   PubMed Web of Science ®Google Scholar
• Evans JM, Hogg MI, Lunn JN, Rosen M. Degree and duration of reversal by naloxone of effects of morphine in conscious subjects. BMJ 1974;2:589-91
   PubMed Web of Science ®Google Scholar
• Wanger K, Brough L, Macmillan I, et al. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med 1998;5:293-9
   PubMed Web of Science ®Google Scholar
• Ngai SH, Berkowitz BA, Yang JC, et al. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology 1976;44:398-401
   PubMed Web of Science ®Google Scholar
• Moreland TA, Brice JE, Walker CH, Parija AC. Naloxone pharmacokinetics in the newborn. Br J Clin Pharmacol 1980;9:609-12
   PubMed Web of Science ®Google Scholar
• Kart T, Christrup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children based on a literature review: Part 1--Pharmacokinetics. Paediatr Anaesth 1997;7:5-11
   PubMed Web of Science ®Google Scholar
• Foldes FF, Davidson GM, Duncalf D, et al. The respiratory, circulatory, and analgesic effects of naloxone-narcotic mixtures in anaesthetized subjects. Can Anaesth Soc J 1965;12:608-21
   PubMedGoogle Scholar
• Sadove MS, Balagot RC, Hatano S, Jobgen EA. Study of a narcotic antagonist--N-allyl-noroxymorphone. JAMA 1963;183:666-8
   PubMed Web of Science ®Google Scholar
• Boyer EW. Management of opioid analgesic overdose. N Engl J Med 2012;367:146-55
   PubMed Web of Science ®Google Scholar
• Anderson JA. Reversal agents in sedation and anesthesia: a review. Anesth Prog 1988;35(2):43-7
   PubMedGoogle Scholar
• Longnecker DE. Anesthesiology. 2nd edition. McGraw-Hill Professional; New York: 2012
   Google Scholar
• Tintinalli JE, Stapczynski JS. Tintinalli’s emergency medicine: a comprehensive study guide. 7th edition. McGraw-Hill; New York: 2011
   Google Scholar
• Longo DL. Harrison’s principles of internal medicine. 18th edition. McGraw-Hill; New York: 2012
   Google Scholar
• Stone CK, Humphries RL. Current diagnosis & treatment emergency medicine. 6th edition. McGraw-Hill; New York: 2008
   Google Scholar
• Rosen P, Marx JA. Rosen’s emergency medicine : concepts and clinical practice. 8th edition. Elsevier/Saunders; Philadelphia, PA: 2013
   Google Scholar
• Connors NC, Nelson LS. Wide variation in naloxone dosing recommendations for acute opioid toxicity. J Med Tox 2014;10:76-7
   Google Scholar
• Atchabahian A, Cupta R. The anesthesia guide. 1 edition. McGraw-Hill Medical; New York: 2013
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): Adult Cancer Pain. 2014. Available from: http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf [Last accessed 19 July 2014]
   Google Scholar
• Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a ‘coma cocktail’. JAMA 1995;274:562-9
   PubMed Web of Science ®Google Scholar
• Kim HK, Nelson LS. Effectiveness of low dose naloxone to reverse respiratory depression in opioid intoxication. Platform presentation at the North American Congress of Clinical Toxicology; Las Vegas, NV 2007
   Google Scholar
• Mills CA, Flacke JW, Flacke WE, et al. Narcotic reversal in hypercapnic dogs: comparison of naloxone and nalbuphine. Can J Anaesth 1990;37:238-44
   PubMed Web of Science ®Google Scholar
• Mills CA, Flacke JW, Miller JD, et al. Cardiovascular effects of fentanyl reversal by naloxone at varying arterial carbon dioxide tensions in dogs. Anesth Analg 1988;67:730-6
   PubMed Web of Science ®Google Scholar
• Lewis JM, Klein-Schwartz W, Benson BE, et al. Continuous naloxone infusion in pediatric narcotic overdose. Am J Dis Child 1984;138:944-6
   PubMedGoogle Scholar
• Bradberry JC, Raebel MA. Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intell Clin Pharm 1981;15:945-50
   PubMedGoogle Scholar
• Coyne PJ, Hansen LA, Laird J, et al. Massive hydromorphone dose delivered subcutaneously instead of intrathecally: guidelines for prevention and management of opioid, local anesthetic, and clonidine overdose. J Pain Symptom Manage 2004;28:273-6
   PubMed Web of Science ®Google Scholar
• Gourlay GK, Coulthard K. The role of naloxone infusions in the treatment of overdoses of long half-life narcotic agonists: application to nor-methadone. Br J Clin Pharmacol 1983;15:269-71
   PubMed Web of Science ®Google Scholar
• Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994;12:650-60
   PubMed Web of Science ®Google Scholar
• Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986;15:566-70
   PubMed Web of Science ®Google Scholar
• Full prescribing information - Evzio. Available from: http://evzio.com/pdfs/Evzio PI.PDF [Last accessed 18 November 2014]
   Google Scholar
• Yassen A, Kan J, Olofsen E, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. J Pharmacol Exp Ther 2006;319:682-92
   PubMed Web of Science ®Google Scholar
• Christoph T, Kogel B, Schiene K, et al. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005;507(1-3):87-98
   PubMed Web of Science ®Google Scholar
• Dum JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981;74(3):627-33
   PubMed Web of Science ®Google Scholar
• Estilo AE, Cottrell JE. Naloxone, hypertension, and ruptured cerebral aneurysm. Anesthesiology 1981;54:352
   PubMed Web of Science ®Google Scholar
• Johnson C, Mayer P, Grosz D. Pulmonary edema following naloxone administration in a healthy orthopedic patient. J Clin Anesth 1995;7:356-7
   PubMed Web of Science ®Google Scholar
• Nath SS, Tripathi M, Pandey C, Rao B. Naloxone-induced pulmonary edema: a potential cause of postoperative morbidity in laparoscopic donor nephrectomy. Indian J Med Sci 2009;63:72-5
   PubMedGoogle Scholar
• Partridge BL, Ward CF. Pulmonary edema following low-dose naloxone administration. Anesthesiology 1986;65:709-10
   PubMed Web of Science ®Google Scholar
• Manfredi PL, Ribeiro S, Chandler SW, Payne R. Inappropriate use of naloxone in cancer patients with pain. J Pain Symptom Manage 1996;11:131-4
   PubMed Web of Science ®Google Scholar
• Flacke JW, Flacke WE, Williams GD. Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. Anesthesiology 1977;47:376-8
   PubMed Web of Science ®Google Scholar
• Prough DS, Roy R, Bumgarner J, Shannon G. Acute pulmonary edema in healthy teenagers following conservative doses of intravenous naloxone. Anesthesiology 1984;60:485-6
   PubMed Web of Science ®Google Scholar
• Taff RH. Pulmonary edema following naloxone administration in a patient without heart disease. Anesthesiology 1983;59:576-7
   PubMed Web of Science ®Google Scholar
• Schwartz JA, Koenigsberg MD. Naloxone-induced pulmonary edema. Ann Emerg Med 1987;16(11):1294-6
   PubMed Web of Science ®Google Scholar
• Tanaka GY. Letter: Hypertensive reaction to naloxone. JAMA 1974;228:25-6
   PubMed Web of Science ®Google Scholar
• Azar I, Turndorf H. Severe hypertension and multiple atrial premature contractions following naloxone administration. Anesth Analg 1979;58:524-5
   PubMed Web of Science ®Google Scholar
• Michaelis LL, Hickey PR, Clark TA, Dixon WM. Ventricular irritability associated with the use of naloxone hydrochloride. Two case reports and laboratory assessment of the effect of the drug on cardiac excitability. Ann Thorac Surg 1974;18:608-14
   PubMedGoogle Scholar
• Cuss FM, Colaco CB, Baron JH. Cardiac arrest after reversal of effects of opiates with naloxone. BMJ 1984;288:363-4
   PubMed Web of Science ®Google Scholar
• Andree RA. Sudden death following naloxone administration. Anesth Analg 1980;59:782-4
   PubMed Web of Science ®Google Scholar
• Kienbaum P, Thurauf N, Michel MC, et al. Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology 1998;88:1154-61
   PubMed Web of Science ®Google Scholar
• Doyon S, Aks SE, Schaeffer S. Expanding access to naloxone in the United States. J Med Toxicol 2014;10:431-4
   PubMedGoogle Scholar
• Davis CS, Ruiz S, Glynn P, et al. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am J Public Health 2014;104:e7-9
   PubMed Web of Science ®Google Scholar
• Davis CS, Southwell JK, Niehaus VR, et al. Emergency medical services naloxone access: a national systematic legal review. Acad Emerg Med 2014;21:1173-7
   PubMed Web of Science ®Google Scholar
• Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Am J Public Health 2009;99:402-7
   PubMed Web of Science ®Google Scholar
• Boyd JJ, Kuisma MJ, Alaspaa AO, et al. Recurrent opioid toxicity after pre-hospital care of presumed heroin overdose patients. Acta Anaesthesiol Scand 2006;50:1266-70
   PubMed Web of Science ®Google Scholar
• Vilke GM, Sloane C, Smith AM, Chan TC. Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med 2003;10:893-6
   PubMed Web of Science ®Google Scholar
• Wampler DA, Molina DK, McManus J, et al. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care 2011;15:320-4
   PubMed Web of Science ®Google Scholar
• Eggertson L. Take-home naloxone kits preventing overdose deaths. CMAJ 2014;186:17
   PubMed Web of Science ®Google Scholar
• Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010;87(6):931-41
   PubMed Web of Science ®Google Scholar
• Straus MM, Ghitza UE, Tai B. Preventing deaths from rising opioid overdose in the US - the promise of naloxone antidote in community-based naloxone take-home programs. Subst Abuse Rehabil 2013;2013
   Google Scholar
• The Network for Public Health Law. Legal intervention to reduce overdose mortality: Naloxone access and overdose Good Samaritan laws. 2014. Available from: https://www.networkforphl.org/_asset/qz5pvn/network-naloxone.pdf [Last accessed 25 June 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:101-5
   PubMedGoogle Scholar
• Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction 2005;100:1823-31
   PubMed Web of Science ®Google Scholar
• Bazazi AR, Zaller ND, Fu JJ, Rich JD. Preventing opiate overdose deaths: examining objections to take-home naloxone. J Health Care Poor Underserved 2010;21:1108-13
   PubMed Web of Science ®Google Scholar
• Cassel JA, Daubert JD, DeHaven RN. [(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol 2005;520:29-36
   PubMed Web of Science ®Google Scholar
• Apaydin S, Oktem HA. Effect of arachidonic acid on specific binding of [3H]naloxone to opioid receptors. Acta Neurobiol Exp(Wars) 2000;60:361-3
   PubMed Web of Science ®Google Scholar